Eton Pharmaceuticals Inc. (ETON)
Eton Pharmaceuticals Inc. (ETON) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | 1.81B |
| Revenue (ttm) | 105.59M |
| Net Income (ttm) | 12.69M |
| Beta | 0.87 |
| EPS (ttm) | 0.4 |
| PE Ratio (ttm) | 158.57 |
| Forward PE | 24.59 |
| P/B (ttm) | 38.51 |
| P/S (ttm) | 17.17 |
| Earnings Date | Nov 12, 2026 |
| Ask | n/a |
| Volume | 863,744 |
| Avg. Volume (20D) | 522,058 |
| Open | 61.10 |
| Previous Close | 61.73 |
| Day's Range | 60.00 - 63.56 |
| 52-Week Range | 14.27 - 63.56 |
| Analyst | Strong Buy |
| Price Target | 70 (10.36%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhy...
Financial Performance
In 2025, Eton Pharmaceuticals's revenue was 79.95M, an increase of 104.94% compared to the previous year's 39.01M. Earnings were -4.6M, an increase of 20.35%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for ETON stock is "Strong Buy". The 12-month stock price forecast is 70, which is upside of 10.36% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
